Ask the Chatbot Games & Quizzes History & Society Science & Tech Biographies Animals & Nature Geography & Travel Arts & Culture ProCon Money Videos

What was the company Karikó and Weissman founded to commercialize non-immunogenic, nucleoside-modified RNA technology?

verifiedCite
While every effort has been made to follow citation style rules, there may be some discrepancies. Please refer to the appropriate style manual or other sources if you have any questions.
Select Citation Style
Feedback
Corrections? Updates? Omissions? Let us know if you have suggestions to improve this article (requires login).
Thank you for your feedback

Our editors will review what you’ve submitted and determine whether to revise the article.

External Websites
Written and fact-checked by
The Editors of Encyclopaedia Britannica
Encyclopaedia Britannica's editors oversee subject areas in which they have extensive knowledge, whether from years of experience gained by working on that content or via study for an advanced degree....
The Editors of Encyclopaedia Britannica
Last updated

In 2006, Katalin Karikó and Drew Weissman started a company called RNARx, which aimed to commercialize non-immunogenic, nucleoside-modified RNA. The researchers eventually licensed the technology to two biotechnology companies, Moderna and BioNTech. In 2013 Karikó took a position as senior vice president at BioNTech, overseeing the company’s work on mRNA.

Related Questions